[1]
Karimkhani, C.; Green, A.C.; Nijsten, T.; Weinstock, M.A.; Dellavalle, R.P.; Naghavi, M.; Fitzmaurice, C. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br. J. Dermatol., 2017, 177(1), 134-140.
[http://dx.doi.org/10.1111/bjd.15510] [PMID: 28369739]
[http://dx.doi.org/10.1111/bjd.15510] [PMID: 28369739]
[2]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin., 2016, 66(1), 7-30.
[http://dx.doi.org/10.3322/caac.21332] [PMID: 26742998]
[http://dx.doi.org/10.3322/caac.21332] [PMID: 26742998]
[3]
Soong, S.J.; Harrison, R.A.; McCarthy, W.H.; Urist, M.M.; Balch, C.M. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J. Surg. Oncol., 1998, 67(4), 228-233.
[http://dx.doi.org/10.1002/(SICI)1096-9098(199804)67:4<228:AID-JSO4>3.0.CO;2-A] [PMID: 9579369]
[http://dx.doi.org/10.1002/(SICI)1096-9098(199804)67:4<228:AID-JSO4>3.0.CO;2-A] [PMID: 9579369]
[4]
Argenziano, G.; Lallas, A.; Longo, C.; Moscarella, E.; Kyrgidis, A.; Ferrara, G. Cutaneous Melanoma: A Pocket Guide for Diagnosis and Management; Academic Press: London, 2017.
[5]
Nikolaou, V.; Stratigos, A.J. Emerging trends in the epidemiology of melanoma. Br. J. Dermatol., 2014, 170(1), 11-19.
[http://dx.doi.org/10.1111/bjd.12492] [PMID: 23815297]
[http://dx.doi.org/10.1111/bjd.12492] [PMID: 23815297]
[6]
Reginelli, A. Belfiore, Russo A, Turriziani F, Moscarella E, Troiani T, Brancaccio G, Ronchi A, Giunta E, Sica A, Iovino F, Ciardiello F, Franco R, Argenziano G, Grassi R and Cappabianca S. A preliminary study for quantitative assessment with HFUS (High Frequency ultrasound) of nodular skin melanoma Breslow thickness in adults before surgery: Interdisciplinary team experience. Curr. Radiopharm., 2020, 13(1), 48-55.
[7]
Quartuccio, N.; Siracusa, M.; Pappalardo, M.; Arnone, A.; Arnone, G. Sentinel Node Identification in melanoma: current clinical impact, new emerging SPECT radiotracers and technological advancements. An update of the last decade. Curr. Radiopharm., 2020, 13(1), 32-41.
[http://dx.doi.org/10.2174/1874471012666191015100837] [PMID: 31749441]
[http://dx.doi.org/10.2174/1874471012666191015100837] [PMID: 31749441]
[8]
Laudicella, R.; Baratto, L.; Minutoli, F.; Baldari, S.; Iagaru, A. Malignant cutaneous melanoma: updates in PET imaging. Curr. Radiopharm., 2020, 13(1), 14-23.
[PMID: 31749439]
[PMID: 31749439]
[9]
Annunziata, S.; Laudicella, R.; Cobelli, F.; Pizzuto, D.A. Young AIMN Working Group. Clinical Value of PET/CT in staging melanoma and potential new radiotracers. Curr. Radiopharm., 2020, 13(1), 6-13.
[10]
Albano, D.; Familiari, D.; Fornito, M.C.; Scalisi, S.; Laudicella, R.; Galia, M.; Grassedonio, E.; Ruggeri, A.; Ganduscio, G.; Messina, M.; Spada, M.; Midiri, M.; Alongi, P. Clinical and prognostic value of 18F-FDG-PET/CT in the restaging process of recurrent cutaneous melanoma. Curr. Radiopharm., 2020, 13(1), 42-47.
[http://dx.doi.org/10.2174/1874471012666191009161826] [PMID: 31595860]
[http://dx.doi.org/10.2174/1874471012666191009161826] [PMID: 31595860]
[11]
Castello, A.; Lopci, E. Role of PET/CT in the era of immune checkpoint inhibitors: state of art. Curr. Radiopharm., 2020, 13(1), 24-31.
[http://dx.doi.org/10.2174/1874471012666191015100106] [PMID: 31749440]
[http://dx.doi.org/10.2174/1874471012666191015100106] [PMID: 31749440]
[12]
Alongi, P.; Evangelista, L.; Caobelli, F.; Spallino, M.; Gianolli, L.; Midiri, M.; Picchio, M. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2018, 45(1), 85-94.
[http://dx.doi.org/10.1007/s00259-017-3811-4] [PMID: 28828589]
[http://dx.doi.org/10.1007/s00259-017-3811-4] [PMID: 28828589]
[13]
Albano, D.; Familiari, D.; Gentile, R.; Scalisi, S.; Midiri, F.; Messina, M.; Spada, M.; Fornito, M.C.; Galia, M.; Midiri, M.; Alongi, P. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer. Nucl. Med. Commun., 2018, 39(8), 741-746.
[http://dx.doi.org/10.1097/MNM.0000000000000862] [PMID: 29782393]
[http://dx.doi.org/10.1097/MNM.0000000000000862] [PMID: 29782393]
[14]
Alongi, P.; Caobelli, F.; Gentile, R.; Stefano, A.; Russo, G.; Albano, D.; Baldari, S.; Gilardi, M.C.; Midiri, M. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging, 2017, 44(2), 224-233.
[http://dx.doi.org/10.1007/s00259-016-3500-8] [PMID: 27565154]
[http://dx.doi.org/10.1007/s00259-016-3500-8] [PMID: 27565154]
[15]
Alongi, P.; Picchio, M.; Zattoni, F.; Spallino, M.; Gianolli, L.; Saladini, G.; Evangelista, L. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(3), 464-473.
[http://dx.doi.org/10.1007/s00259-015-3159-6] [PMID: 26268680]
[http://dx.doi.org/10.1007/s00259-015-3159-6] [PMID: 26268680]
[16]
Sinagra, E.; Sciumè, C. Ileal melanoma, a rare cause of small bowel obstruction: report of a case, and short literature review. Curr. Radiopharm., 2020, 13(1), 56-62.
[http://dx.doi.org/10.2174/1874471012666191015101410] [PMID: 31749442]
[http://dx.doi.org/10.2174/1874471012666191015101410] [PMID: 31749442]
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Current Developments in the Detection and Control of Multi Drug Resistance
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Article Metrics
24
8
1
1